Data issue put Leo Pharma in the Danish Medicines Agency's crosshairs in 2021
![Photo: Leo Pharma/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14143027.ece/ALTERNATES/schema-16_9/doc7lfgcwtp7v91fk0ado6.jpg)
Leo Pharma didn’t exactly welcome a good clinical practice (GCP) inspection by the Danish Medicines Agency with open arms last year and would have faced ”regulatory action” if it failed to hand over documents pertaining to clinical studies of eczema treatments tralokinumab and delgocitinib, industry media Dagens Pharma reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Leo Pharma looking for pediatric patients for eczema trial
For subscribers
CHMP to remove 100 generic medicines from market
For subscribers